LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408 Phase 3 COMPLETED

The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.

Details

Lead sponsor	Chromaderm, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	200
Start date	2002-07
Completion	2005-10

Conditions

• Diabetic Neuropathies
• Diabetes Mellitus, Insulin-Dependent
• Diabetes Mellitus, Non-Insulin-Dependent

Interventions

• Ruboxistaurin mesylate

Primary outcomes

• Reduction in neuropathic symptoms

Countries

United States, Canada, Croatia, Finland, India, Lithuania, Netherlands, United Kingdom